Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Eculizumab (Alexion).

Mariana Kaplan1

  • 1University of Michigan Medical Center, Division of Rheumatology, Ann Arbor 48109-1065, USA. makaplan@umich.edu

Current Opinion in Investigational Drugs (London, England : 2000)
|August 21, 2002
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Anti-Mi2 autoantibodies target PHD fingers of SP140L and TIF1γ, while anti-TIF1γ autoantibodies primarily bind TIF1γ outside the PHD region.

Rheumatology (Oxford, England)·2025
Same author

Anti-Mi2 autoantibodies target the PHD fingers of SP140L and TIF1γ, while anti-TIF1γ autoantibodies primarily recognize epitopes outside the PHD region of TIF1γ.

medRxiv : the preprint server for health sciences·2025
Same author

Editorial overview: Autoimmunity 2022.

Current opinion in immunology·2023
Same author

HAL-X: Scalable hierarchical clustering for rapid and tunable single-cell analysis.

PLoS computational biology·2022
Same author

A highlight from the LUPUS 2014 meeting: eight great ideas.

Lupus science & medicine·2015
Same author

Sera from patients with type 2 diabetes and neuropathy induce autophagy and colocalization with mitochondria in SY5Y cells.

Autophagy·2006
Same journal

Reporting disease control rates or clinical benefit rates in early clinical trials of anticancer agents: useful endpoint or hype?

Current opinion in investigational drugs (London, England : 2000)·2011
Same journal

Abating progressive tissue injury and preserving function after CNS trauma: The role of inflammation modulatory therapies.

Current opinion in investigational drugs (London, England : 2000)·2010
Same journal

Teriflunomide, an inhibitor of dihydroorotate dehydrogenase for the potential oral treatment of multiple sclerosis.

Current opinion in investigational drugs (London, England : 2000)·2010
Same journal

Tralokinumab, an anti-IL-13 mAb for the potential treatment of asthma and COPD.

Current opinion in investigational drugs (London, England : 2000)·2010
Same journal

Vedolizumab, a humanized mAb against the α4β7 integrin for the potential treatment of ulcerative colitis and Crohn's disease.

Current opinion in investigational drugs (London, England : 2000)·2010
Same journal

Pitrakinra, a dual IL-4/IL-13 antagonist for the potential treatment of asthma and eczema.

Current opinion in investigational drugs (London, England : 2000)·2010
See all related articles

Eculizumab, a novel antibody, is being developed to treat chronic inflammatory diseases like rheumatoid arthritis and nephritis by inhibiting complement C5. Clinical trials are underway, with potential launches and significant sales predicted for these indications.

Area of Science:

  • Immunology
  • Pharmacology
  • Rheumatology

Background:

  • Eculizumab (5G1.1) is a humanized monoclonal antibody targeting human complement component C5.
  • It functions by preventing the cleavage of C5, thereby inhibiting pro-inflammatory downstream effects.
  • Alexion is developing eculizumab for chronic inflammatory conditions.

Purpose of the Study:

  • To evaluate eculizumab as a potential therapeutic agent for rheumatoid arthritis (RA) and nephritis.
  • To assess its efficacy in other autoimmune conditions such as dermatomyositis and pemphigoid.
  • To explore the development of a single-chain version, pexelizumab, for cardiovascular indications.

Main Methods:

  • Phase IIb clinical trials initiated for rheumatoid arthritis in January 2002.

Related Experiment Videos

  • Phase II trials ongoing for membranous nephritis and lupus nephritis in April 2002.
  • Earlier stage clinical trials for dermatomyositis and pemphigoid.

    • Main Results:

    • Eculizumab received Orphan Drug status from the FDA for dermatomyositis (October 2000) and membranous nephritis (February 2002).
    • Analysts projected eculizumab launch for dermatomyositis and pemphigus in 2003, and RA and nephritis in 2004.
    • Peak worldwide sales were predicted at $175 million for RA and $400 million for nephritis, with detailed sales forecasts for 2006 and 2008.

    Conclusions:

    • Eculizumab demonstrates potential as a treatment for rheumatoid arthritis and nephritis.
    • Its development is progressing through various clinical trial phases for multiple autoimmune and inflammatory diseases.
    • Significant market potential is anticipated based on analyst predictions for future sales.